Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course CDA-II injection in low-risk or intermediate-1 myelodysplastic syndrome
ChiCTR1900022183Phase 4Recruiting
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cladribine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. Primary endpoint: hematological improvement rate. Started Apr 2019; status: recruiting.
02
Drugs
cladribine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1900022183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022183.